Delving into the Latest Updates on HB-2121 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

HB-2121

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Celiac Disease

Inactive Indication-

Originator Organization

Stanford University

Active Organization

Stanford University

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to learn about the safety of a single dose of HB-2121 in adults. It will also look at how the body processes the drug. The main questions it aims to answer are:
* What side effects do participants have after receiving HB-2121?
* How much HB-2121 is in the blood over time?
Researchers will follow participants for 30 days after receiving HB-2121 to understand how the drug behaves in the body and how safe it is.
Participants will:
* Receive one oral dose of HB-2121
* Attend 4 in-person clinic visits for checkups, lab tests, and monitoring
* Complete 2 remote visits that include safety lab assessments
* Fill out a short daily questionnaire for 7 days about symptoms and health status

Start Date26 Aug 2025

Sponsor / Collaborator

Stanford University

100 Clinical Results associated with HB-2121

Login to view more data

100 Translational Medicine associated with HB-2121

Login to view more data

100 Patents (Medical) associated with HB-2121

Login to view more data

100 Deals associated with HB-2121

Login to view more data